<DOC>
	<DOCNO>NCT01054313</DOCNO>
	<brief_summary>The goal clinical research study find high tolerate dose combination Taxotere ( docetaxel ) Rapamycin ( sirolimus ) give patient advanced cancer . Researchers also want find high tolerate dose combination docetaxel , sirolimus , prednisone give patient advanced prostate cancer . The safety drug combination also study .</brief_summary>
	<brief_title>Docetaxel Sirolimus Patients With Advanced Malignancies</brief_title>
	<detailed_description>The Study Drugs : Docetaxel design stop growth cancer cell , may cause cell die . It believe weakly effective kill blood vessel tumor tissue well . Sirolimus design block protein call mammalian target rapamycin ( mTOR ) inside cancer cell . Prednisone corticosteroid similar natural hormone make body . Prednisone often give combination chemotherapy treat cancer . Study Groups : If find eligible take part study , assign dose level combination docetaxel sirolimus base join study . Up 12 dose level docetaxel sirolimus test . Three ( 3 ) 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose docetaxel sirolimus find . Once high tolerable dose docetaxel sirolimus find , 12 patient may enrol study safety drug dose . If prostate cancer , also receive prednisone . All participant receive prednisone receive dose level . Study Drug Administration : Each study cycle 21 day . Everyday , take sirolimus mouth 1 time day . Sirolimus take without food , take time everyday . On Day 1 every cycle , receive docetaxel vein 1 hour . If take prednisone , take 2 time every day mouth food water . Study Visits : Every week first 3 week every 3 week , blood ( 5 teaspoon ) draw routine test . You also physical exam . Every 6 week , woman able child blood drawn pregnancy test . About every three week , blood ( 5 teaspoon ) draw routine test , check kidney function , biomarker test . About every 6 week , CT scan x-ray check status disease . Length Study : You study long benefitting . You take study disease get bad experience intolerable side effect . Follow-Up : If experience intolerable side effect , follow side effect resolve side effect continue improve get bad . The study doctor tell test need perform . This investigational study . Docetaxel FDA approve commercially available treatment advance cancer breast , lung , prostate cancer . Sirolimus FDA approve commercially available prevention transplant rejection kidney transplant patient . Prednisone FDA approve commercially available treatment prostate cancer give docetaxel . The combination docetaxel sirolimus , without prednisone , treat advance cancer investigational . Most patient study receive docetaxel sirolimus . However , prostate cancer , receive docetaxel , prednisone , sirolimus . Up 68 patient enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy available improves survival least three month . 2 . Patients must least 5 halflives three week , whichever short , previous target biologic therapy ; patient must least three week beyond previous cytotoxic therapy . In addition , patient must &gt; /= 3 week beyond previous therapeutic radiation major surgery . Patients may receive palliative localize radiation immediately treatment provide radiation deliver site disease treat protocol . Terminal phase half life docetaxel 11.1 hour ; sirolimus , 14.5 hour . 3. cont 'd criterion # 2 Previous mTOR inhibitor ( everolimus , temsirolimus , sirolimus ) taxane ( include paclitaxel , abraxane/ABI007 , docetaxel ) therapy permit . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 3 5 . Patients must normal organ marrow function define : absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /=50,000/mL ; creatinine &lt; /= 2 x upper limit normal ( ULN ) ; total bilirubin &lt; /= 3x ULN ; ALT ( SGPT ) &lt; /= 3 x ULN ; cholesterol &lt; /= 350 mg/dL ; triglyceride &lt; /= 400 mg/dL . 6 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day last dose . 7 . Patients must able understand willing sign write informed consent document . 8 . Patients already gonadotropinreleasing hormone ( GnRH ) agonist therapy ( eg goserelin acetate , leuprolide acetate ) metastatic , castrateresistant prostate cancer three month prior entry study may continue intervention enrol protocol . Patients somatostatin analogue ( eg octreotide ) symptom control three month prior entry study may continue intervention enrol protocol . 1 . Uncontrolled intercurrent illness include , limited , uncontrolled infection , uncontrolled asthma , need hemodialysis , need ventilatory support . 2 . Pregnant lactating woman . 3 . History hypersensitivity docetaxel component formulation . 4 . History hypersensitivity sirolimus component formulation 5 . Patients maintain medication strong inducer inhibitor CYP3A4 medication discontinue prior entry study unless cessation medication would detrimental patient 's health . 6 . Patients unwilling unable sign inform consent document .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Advanced Malignancies</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamune</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Resistant standard therapy</keyword>
</DOC>